NORTHERN-DATA-AG
21.7.2020 07:34:11 CEST | Business Wire | Press release
Northern Data AG (XETRA: NB2, ISIN: DE000A0SMU87 ), one of the world's largest providers of high-performance-computing (HPC) solutions, has developed proprietary HPC services in cooperation with the leading Taiwanese computer hardware manufacturer Gigabyte Technology (Taiwan Stock Exchange: 2376, ISIN: TW0002376001 ).
Northern Data's partnership with Gigabyte covers the production, supply and combination of components, where Northern Data tests specific processors (GPUs, CPUs, etc.) and selects them for the respective applications and Gigabyte combines these processors with its specialised server architecture. In doing so, Gigabyte adjusts the GPU clusters developed by Northern Data to meet all of Northern Data's technical requirements. A GPU cluster is a computer network in which each node (processing unit) is equipped with several Graphic Processing Units (GPU). The high-density GPU clusters used in these processes are specially designed for high-performance-computing (HPC) applications.
The server architecture created on this basis is the foundation for so-called distributed computing. Distributed computing involves running software across multiple computer systems working in parallel, in order to increase their efficiency, reliability and performance. With these new, tailor-made high-density GPU clusters, Northern Data can meet the highly specific requirements of their customers, providing them with the required computing power for their respective HPC applications as easily and efficiently as possible. This service will then be used in Northern Data's data centers for individually developed customer solutions.
GPU-based, parallel processing of data enables highly complex, computationally intensive HPC applications to be executed efficiently, reliably and quickly, particularly in the domains of artificial intelligence and rendering.
This combination of Gigabyte's expertise in manufacturing HPC hardware and Northern Data's experience in managing and orchestrating large-scale facilities (with proprietary AI software and its own thermal management system) opens up new opportunities for Northern Data customers to scale their operations even further than before. Northern Data distinguishes itself from other providers by the composition and combination of hardware and software, the way it is made available and, above all, by the favourable pricing for customers.
"The demand for HPC is booming; the rendering and AI sectors are enormous growth markets. We are pleased to have Gigabyte Technologies, one of the leading suppliers in the young HPC sector, on board as our development partner, and we are now excited to announce this business partnership," explains Aroosh Thillainathan, CEO of Northern Data AG, and continues: "We have already worked together on various GPU-based HPC projects, as we believe that Gigabyte's servers are among the best hardware for HPC in the world. Hence, we are very pleased to deepen our partnership with a manufacturer with this level of expertise and to have them accompany our R&D process. Gigabyte is the right strategic partner to help us make the concept of distributed computing a reality for many HPC applications".
Northern Data CFO Mathis Schultz adds: "So far, our customers are predominantly in the bitcoin mining sector, which was the first mass-scale HPC application. But the demand from other sectors is growing rapidly, accelerated in part by the Covid-19 crisis. The partnership with Gigabyte Technologies allows us to build out our market-leading position with bitcoin mining clients, into new sectors."
And Thomas Yen, European head of Gigabyte Technologies explains: "We are pleased to now officially announce our partnership with Northern Data. We see great potential in our jointly-designed GPU clusters. We are excited to work closely with Northern Data as a strategic partner and high-potential customer in the field of HPC."
About Northern Data:
Northern Data AG builds and offers global infrastructure solutions in the field of high-performance computing (HPC), offering solutions in the fields of machine learning and artificial intelligence, big data analytics, blockchain applications, game streaming and more. Operating internationally the company evolved from the merger of German Northern Bitcoin AG and American Whinstone US, Inc. and is now a recognized leader in the provision of HPC solutions worldwide. The company offers HPC solutions, both stationary in large state-of-the-art data centers as well as in high-tech mobile data centers, which can be deployed in any location worldwide. In doing so, it combines self-developed software and hardware with novel concepts to ensure a sustainable and reliable energy supply. In Texas, Northern Data is running the USA's largest HPC data center and, at the same time, the world's largest dedicated HPC facility. Further information can be found at www.northerndata.de .
About Gigabyte Technology Co., Ltd.
Gigabyte Technology Co., Ltd. is a Taiwan-based company principally engaged in the production, processing and sales of information technology (IT) products. The company provides computer motherboards, three dimensional (3D) display graphic cards, laptops, tablets, personal computers (PCs), servers, smart phones, broadband network devices and wireless communication products, computer peripherals and network storage products. It distributes its products mainly within Taiwan, as well as to the rest of Asia, Europe and the Americas.
Disclaimer:
This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Data AG and does not constitute a prospectus of Northern Data AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice.
| Language: | English |
| Company: | Northern Data AG |
| Thurn-und-Taxis-Platz 6 | |
| 60313 Frankfurt/Main | |
| Germany | |
| Phone: | +49 69 34 87 52 25 |
| E-mail: | info@northerndata.de |
| Internet: | www.northerndata.de |
| ISIN: | DE000A0SMU87 |
| WKN: | A0SMU8 |
| Listed: | Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich (m:access), Tradegate Exchange |
| EQS News ID: | 1097883 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20200720005840/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
